Fulcrum Therapeutics, Inc. (FULC) vs Vanda Pharmaceuticals Inc. (VNDA)

A side-by-side comparison of Fulcrum Therapeutics, Inc. and Vanda Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — FULC vs VNDA

growth of $100 · dividends reinvested · last 7y
FULC -72.5% (-16.8%/yr)VNDA -65.9% (-14.3%/yr)VNDA compounded faster over this window
050100150200Start $100202120232025$27$34
FULC VNDA

FULC vs VNDA: by the numbers

  • •FULC is the larger company ($282M vs $272M market cap).
  • •Both run net losses; FULC's is the smaller (0.00% vs -127.41% net margin).

Metrics side by side

Valuation

MetricFULCVNDA
P/S ratioN/A1.26
P/B ratio0.911.23

Profitability

MetricFULCVNDA
Gross margin0.00%92.82%
Operating margin0.00%-69.95%
Net margin0.00%-127.41%
ROE-27.36%-124.83%
ROIC-27.62%-74.73%

Growth (annualized)

MetricFULCVNDA
Revenue CAGR (5Y)N/A-3.56%
Total return CAGR (5Y)-31.70%-23.91%

Frequently asked

How have FULC and VNDA total returns compared?
Over the past 5 years, FULC delivered -31.70% and VNDA delivered -23.91% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.